Accès ouvert · CC BY

Protein Kinase C inhibitor Molecule Effect Partial Reversal of Spliceopathy in Myotonic Dystrophy Type 2 Cell Line

Article scientifique 2020 Sciences de la santé Anglais

Résumé

Myotonic dystrophy is a neuromuscular disease which manifest as two forms namely type 1 (DM1) and type 2 (DM2). One of the major molecular events associated with the disease condition is misregulation of splicing resulting in spliceopathy. This study was performed to assess the effect of protein kinase C (PKC) inhibitors- Ro 31-8220 and hypericin- on the splicing of insulin receptor (IR) and muscleblind-like (MBNL1) in myotonic dystrophy type 2 (DM2) cell line. The results of this study demonstrated that only Ro 31-8820 was able to effect partial rescue of missplicing of insulin receptor and muscleblind-like 1. It indicates that it could be a possible therapeutic agent for treatment of DM2. Keywords : Myotonic dystrophy, Protein Kinase C inhibitor, spliceopathy, therapeutics DOI: 10.7176/JNSR/11-14-03 Publication date: July 31 st 2020

Citer ce document

Udosen, I. (2020). Protein Kinase C inhibitor Molecule Effect Partial Reversal of Spliceopathy in Myotonic Dystrophy Type 2 Cell Line. https://doi.org/10.7176/jnsr/11-14-03

Exporter : BibTeX · RIS (Zotero, Mendeley, EndNote)

Accès au document

Texte intégral archivé sur SPHAERO, en accès ouvert : lisible gratuitement en ligne après connexion. Le document reste aussi disponible à sa source. Se connecter

Voir l'article sur le site de la revue

Licence et provenance

Licence : CC BY

Notice moissonnée depuis OpenAlex le 04/09/2026. Le document reste hébergé par sa source.
Voir le document à la source →

Auteur(s)

Statistiques

Consultations (hors robots) : 8

Téléchargements (hors robots) : 0

Méthode de comptage